MDGL madrigalpharma.com Earnings growth forecast for next year

Corporate emblem and logo of Madrigal Pharmaceuticals, Inc. (MDGL)

The consensus earnings per share forecast vector reflects market expectations, where the 445.50 metric serves as the target level for Madrigal Pharmaceuticals (MDGL). Drug development is accelerating through AI-driven molecular screening while maintaining physician oversight. Revenues are based on the exclusive distribution of the drug Rezdiffra. First-mover status in the treatment of liver fibrosis provides Madrigal Pharmaceuticals (MDGL) with a robust moat against future competitors.

Madrigal Pharma (MDGL): Expected net earnings per share growth next year from 07/04/2022 to 11/16/2026

MDGL (Madrigal Pharmaceuticals Inc): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:MDGL, madrigalpharma.com
Finished products of Madrigal Pharmaceuticals, Inc.

The expected growth in net income for the coming period is measured by the consensus EPS forecast, reflecting the potential for business margin expansion. This metric allows for an assessment of Madrigal Pharmaceuticals (MDGL) credit stability and the probability of a market valuation revision. By analyzing the target EPS growth rate for the next year, an investor gains a weighted assessment of profitability stripped of market noise. For Madrigal Pharmaceuticals (MDGL), this is critically important, as business viability currently depends on insurance coverage for the first MASH drug.

Analysis of competing companies

ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Corcept Therapeutics|Earnings growth forecast for next year RYTM|Net earnings per share growth forecast for next year AKRO (Akero Therapeutics, Inc.)|Net earnings per share growth forecast for next year metsera.com MTSR|MoonLake Corp (MLTX) - Expected net earnings per share growth next year|CRNX - Net earnings per share growth forecast for next year|NAMS: Net earnings per share growth forecast for next year|SLNO: Earnings growth forecast for next year|FOLD - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year 89bio Pharma|Agios Corp (AGIO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year structuretx.com (GPCR)|Expected earnings per share growth for next year mimedx.com MDXG|Net earnings per share growth forecast for next year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Net earnings per share growth forecast for next year|MBX: Expected earnings per share growth for next year|Altimmune Corp - Projected earnings per share increase next year|Aardvark Therapeutics Inc (AARD) - Net earnings per share growth forecast for next year|Net earnings per one share growth forecast for next year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Biomea Fusion (BMEA)|Earnings growth forecast for next year QNCX|Projected earnings per share increase next year GUTS|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year